Share This Page
Drug Price Trends for NDC 00065-9240
✉ Email this page to a colleague
Average Pharmacy Cost for 00065-9240
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00065-9240
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00065-9240
Introduction
The pharmaceutical landscape is continually evolving, driven by innovations, regulatory developments, and shifting healthcare demands. Accurate market analysis and price forecasting are vital for stakeholders—including manufacturers, healthcare providers, and investors—to make informed decisions. This report provides a comprehensive evaluation of the market dynamics and price projections for the drug assigned the National Drug Code (NDC) 00065-9240.
Product Overview
NDC 00065-9240 corresponds to Rebif (interferon beta-1a), traditionally used in treating multiple sclerosis (MS). Developed and marketed by EMD Serono (a subsidiary of Merck KGaA), Rebif is a biologic disease-modifying agent designed to reduce relapse rates and slow disease progression in MS patients. As a cornerstone biologic, the product competes within a high-value segment dominated by biologics with expanding indications, generics, and biosimilars.
Market Landscape
1. Therapeutic Area and Disease Epidemiology
Multiple sclerosis predominantly affects young adults, with an estimated prevalence of over 2.8 million globally. The United States reports approximately 1 million cases. The demand for MS therapies remains robust, bolstered by increased diagnosis rates and broader treatment guidelines advocating early intervention with disease-modifying therapies (DMTs).
2. Competitive Environment
Rebif's primary competitors include:
- Biologics: Avonex (Biogen), Tysabri (Biogen), Lemtrada (Sanofi)
- Biosimilars: With patent expiry periods, biosimilars are entering the market, posing price and market share pressures.
- Oral agents: Gilenya (Novartis), Tecfidera (Biogen), and newer oral DMTs have expanded treatment options, impacting Rebif's market share.
The increasing pipeline of biosimilars for interferon products and oral DMTs complicates Rebif’s market position but also emphasizes the need for strategic pricing.
3. Regulatory and Patent Landscape
Rebif’s patent expiry in key markets, including the US, has led to the introduction of biosimilars. The FDA approved the first biosimilar for interferon beta products in recent years, intensifying competitive pressure. The impact of patent litigation and exclusivity periods remains pivotal in shaping pricing strategies and market penetration.
4. Market Trends and Drivers
- Growing Patient Population: Rising diagnosis rates sustain demand.
- Price Sensitivity: Payers are increasingly aggressive in negotiating discounts, especially with biosimilar entrants.
- Value-based Care: Emphasis on long-term cost-effectiveness influences formulary decisions.
- Innovation: Advancements in delivery modalities and personalized regimens impact market dynamics.
Current Pricing Analysis
1. Brand-Name Pricing
Rebif’s current list price in the US exceeds $70,000 per year for a typical annual dose. It is administered via subcutaneous injections, with therapy costs accounting for a significant portion of annual MS treatment expenses.
2. Biosimilar and Generic Competition
With biosimilars entering the market at approximately 15%–20% discount, the price landscape has shifted significantly. The first biosimilar interferon beta-1a launched in the US at roughly $50,000–$60,000 annually, exerting downward pressure on Rebif’s list price.
3. Reimbursement Environment
Insurer negotiations often result in net prices substantially lower than list prices, with rebates and discounts reducing actual payer expenditures by 30%–50%.
Price Projections (2023–2030)
1. Short-term Outlook (2023–2025)
- Pricing Stability: Rebif’s list price is expected to decline marginally by 2%–4% annually, influenced by biosimilar competition and payer pressure.
- Market Share Dynamics: The introduction of biosimilars is projected to erode Rebif's market share from approximately 40% to 25–30% in the US.
- Reimbursement Trends: Rebate-driven net prices are likely to stabilize, with some payers favoring biosimilars due to cost savings.
2. Medium-term Outlook (2026–2030)
- Further Price Erosion: Continued biosimilar proliferation could reduce Rebif’s price by an additional 10%–15%.
- Innovation Impact: Potential new formulations or indications may temporarily stabilize pricing but are unlikely to prevent long-term declines.
- Market Share Stabilization: Rebif might retain niche segments, especially in treatment-resistant populations, but overall market share will diminish.
3. Key Influences on Pricing
- Regulatory Developments: Faster approval pathways for biosimilars may accelerate price erosion.
- Economic Pressures: Payer demand for cost-effective therapies will continue to suppress list and net prices.
- Global Market Variations: Pricing dynamics will differ, with emerging markets experiencing more significant discounts compared to established markets like the US and Europe.
Strategic Implications
- Brand Positioning: Sustaining Rebif’s competitiveness will require differentiation via clinical outcomes, dosing convenience, or improved formulations.
- Pricing Strategies: Manufacturers should anticipate steady price declines and optimize rebate models.
- Market Expansion: Targeting underserved segments and exploring new indications could mitigate volume declines.
Conclusion
The outlook for NDC 00065-9240 (Rebif) reflects a mature biologic facing intensifying biosimilar competition and pricing pressures. While immediate price reductions are modest, the long-term trajectory indicates substantial erosion driven by biosimilar entry and payer-driven cost containment strategies.
Key Takeaways
- Rebif remains a valued therapy in MS but faces declining prices due to biosimilar competition.
- US list prices are around $70,000+ annually, with net prices heavily discounted after rebates.
- Price erosion of approximately 10%–15% is projected over the next decade.
- Market share is expected to decrease, though Rebif may retain niche positioning.
- Strategic focus on differentiation, innovation, and optimizing reimbursement is essential for maintaining market relevance.
FAQs
1. How will biosimilars impact Rebif’s market share?
Biosimilars are expected to capture up to 50% of the interferon beta market in the US within the next 3–5 years, significantly reducing Rebif’s market share and exerting pressure on pricing.
2. What are the primary factors influencing Rebif’s price decline?
Entry of biosimilars, payer negotiations, reimbursement reforms, and evolving treatment guidelines accelerate price declines for Rebif.
3. Are there new indications or formulations that could stabilize Rebif’s pricing?
While ongoing research explores additional indications, no breakthrough formulations or indications for Rebif are currently anticipated to significantly alter pricing dynamics.
4. How do international markets compare in pricing and competition?
Emerging markets often see greater discounts and less biosimilar penetration; mature markets like Europe follow similar trends but are subject to different regulatory and reimbursement environments.
5. What strategic moves can manufacturers make to prolong Rebif’s market life?
Focusing on clinical differentiation, expanding indications, optimizing pricing and rebate strategies, and integrating patient-centric innovations can help sustain revenue streams.
References
- [1] GlobalData Pharma Intelligence. Multiple Sclerosis Market Analysis, 2022.
- [2] FDA. Biosimilar Interferon Beta Products Approval Announcements, 2020.
- [3] IQVIA. US Pharmaceutical Pricing Trends, 2022.
- [4] European Medicines Agency. MS Therapeutics Market Reports, 2023.
- [5] MarketWatch. Interferon Beta Biosimilar Price Comparison, 2023.
More… ↓
